StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $0.43 | $0.43 | +0.30% | 0.2M |
| 05-15 | $0.43 | $0.45 | +3.82% | 0.1M |
| 05-18 | $0.44 | $0.44 | -1.49% | 0.1M |
| 05-19 | $0.42 | $0.40 | -4.15% | 0.1M |
| 05-20 | $0.40 | $0.41 | +2.10% | 0.4M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 |
|---|---|---|
Revenue | $100.00K | $100.00K |
Operating Income | $-4.50M | $-3.42M |
Net Income | $-9.23M | $-6.98M |
EPS (Diluted) | $-357.14 | $-3.60 |
Total Assets | $3.07M | $8.78M |
Total Liabilities | $57.13M | $5.82M |
Cash & Equivalents | $191.00K | $533.00 |
Free Cash Flow OCF − CapEx | Not available | Not available |
Shares Outstanding | 25.84K | 5.19M |
No sell-side coverage available for PFSA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.